Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate

doi:10.19803/j.1672-8629.2022.04.22

Abstract

Abstract: Objective To study the clinical pharmaceutical practice in the process of treating primary central nervous system lymphoma (PCNSL) with high dose methotrexate (HD-MTX). Methods One patient with PCNSL was treated with HD-MTX. The clinical pharmacist took active part in the clinical treatment of this patient using pharmaceutical knowledge, assisted doctors in formulating chemotherapy and rescue plans, gave pharmaceutical care to this patient, and provided individualized pharmaceutical service to ensure the safety and effectiveness of medication. Results Drug treatment of this case of PCNSL was safe, effective and smooth. Conclusion Clinical pharmacists can play a role in the process of clinical drug treatment, improve the level of clinical drug treatment, and ensure the safety and effectiveness of drug use.

Key words: primary central nervous system lymphoma, methotrexate, clinical pharmacist, rational drug use, pharmaceutical serve

CLC Number:

R969.3

CHEN Fangfang, ZHANG Hongxu. Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.

References

[1] LI XY, FENG JF.Treatment of primary central nervous system lymphoma[J]. Journal of International Oncology(国际肿瘤医学杂志), 2016, 43(1): 71-74.
[2] YU Y, GAO XG.Progress in diagnosis and treatment of primary central nervous system lymphoma[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2019, 26(16): 1145-1149.
[3] LI YJ, LIU YT, ZHOU H.Rituximab with high-dose methotrexate in primary central nervous system lymphoma[J]. The Journal of Evidence-Based Medicine(循证医学), 2018, 18(2): 78-82.
[4] Chinese Society of Clinical Oncology, Anti Leukemla Alliance of Chinese Society of Clinical Oncology. Expert consensus on high dose methotrexate calcium folinate rescue therapy for malignant tumor[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(15): 761-767.
[5] Cancer Clinical Chemotherapy Committee of China Anti-cancer Association, Cancer Support Therapy Committee of China Anti-cancer Association. Chinese expert consensus on prevention and treatment of malignant vomiting related to tumor drug therapy(2014)[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2014, 19(3): 263-273.
[6] Chinese Society of Clinical Oncology, Chinese Society of Hemato-logy, Oncologist Assessment Committee of Chinese Medical Association. Chinese expert consensus on prevention and treatment of HBV reactivation in lymphoma immunochemotherapy[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2013, 18(10): 935-942.
[7] JIANG FL, SHI WJ, LUAN F, et al.Clinical research on HBV reactivation after TP chemotherapy in patients with gynecologic tumors with HBsAg(-) and HBcAb(+)[J]. China Modern Doctor(中国现代医生), 2016, 54(12): 81-84.
[8] LI YJ, JIANG WQ, LI S, et al.A study to compare the pharmaco-dynamics and pharmacokinetics of two regimens of high-dose methotrexate in patients with lymphoma[J]. The Practical Journal of Cancer(实用癌症杂志), 2010, 25(2): 153-157.
[9] XU WQ, TANG YM, FANG CQ, et al.Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia[J]. Chinese Journal of Hematology(中华血液学杂志), 2015, 26(1): 15-18.
[10] ZHU TT, ZHAO YL, FENG LY, et al.Research progress on the influe-ncing factors and mechanism of elimination delay after high-dose methotrexate chemotherapy[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2017, 25(1): 49-54.
[11] LAI R, YANG RR.TDM of High dose methotrexate in the treatment of adult diffuse large B-cell lymphoma[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2019, 12(10): 65-66.
[12] HE HL, LI G, LI J, et al.Application of blood concentration monitoring in childhood acute lymphoblastic leukemia treated with high-dose methotrexate[J]. Practical Journal of Clinical Medicine(实用医院临床杂志), 2016, 9(3): 74-77.
[13] WU W, YAO DF, XU Q.Clinical pharmacist’s involvement in treatment of delayed excretion of large doses of methotrexate in post-drug period: case analysis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2017, 14(8): 741-743.
[14] HUANG L, XU YJ, FENG WY.Pharmaceutical practice of clinical pharmacists participating in rescue treatment of large dose methionine poisoning[J]. China Pharmacy(中国药房), 2016, 24(46): 4399-4401.

[1]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian. Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
[4]	HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
[5]	CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
[6]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[7]	LUO Fangmei, WU Pan, LI Jing, WANG Ting, WANG Fangjie. Correlations of ABCB1 C3435T genetic polymorphism with serum concentrations and adverse reactions of high-dose methotrexate in children with mature B-cell lymphoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 675-679.
[8]	FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin. Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
[9]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
[10]	LIU Bin, SHAO Meiling, CAI Yiran, MA Fengyi, LAN Hong. Applicability of PDCA cycle in standardization of outpatient prescriptions [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1035-1039.
[11]	WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin. Pareto chart analysis of 705 problematic prescriptions in neurology [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903.
[12]	YUAN Xiaolong, WAN Qihua, TAO Donghong, QI Hao, WANG Aixia. Pharmaceutical care of a severely poisoned patient with methotrexate tablets [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 924-928.
[13]	SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.
[14]	TANG Jingya. Pharmaceutical care by a clinical pharmacists in the treatment of parenteral nutrition related hepatic damage: a case report [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 786-788.
[15]	MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao. Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.